「esi」の検索結果

Guides agents through the 3-step experiment creation flow: defining the hypothesis, configuring rollout, and setting up analytics. Delegates rollout decisions to configuring-experiment-rollout and metric setup to configuring-experiment-analytics. TRIGGER when: user asks to create a new experiment or A/B test, OR when you are about to call experiment-create. DO NOT TRIGGER when: user is updating an existing experiment, managing lifecycle, or only browsing experiments.

日本語の概要は準備中です。原文の説明を表示しています。

Diagnoses bias, anomalies, and strange-looking results on a specific PostHog experiment. Covers empty / 0-exposure experiments, sample ratio mismatch, identity fragmentation, multi-variant exposure, uneven-split exclusion bias, significance traps (peeking, A/A, Bayesian vs Frequentist), PostHog-vs-SQL discrepancies, and surprises after mid-run edits. Symptom-driven dispatch to the right diagnostic. TRIGGER when: user asks 'is my experiment biased?' or 'why 0 exposures?', references the bias banner, says a variant looks strange / wrong / off, sees significance flipping, notices PostHog numbers disagreeing with their SQL, sees an A/A test showing significance, or reports surprises after mid-run edits. DO NOT TRIGGER when: creating a new experiment (use creating-experiments), only configuring rollout (use configuring-experiment-rollout) or metrics (use configuring-experiment-analytics), or only asking lifecycle questions (use managing-experiment-lifecycle).

日本語の概要は準備中です。原文の説明を表示しています。

Create a recurring AI-generated PostHog report — schedule a free-text prompt to run on a cron, with the LLM-synthesized markdown delivered to email or Slack on each tick. Use when the user wants a recurring AI summary of X on any cadence (daily, weekly, monthly, yearly) rather than a one-off report. (To attach an AI summary to an existing insight/dashboard subscription instead of a free-text prompt, see `managing-subscriptions` and its `summary_enabled` option.)

日本語の概要は準備中です。原文の説明を表示しています。

Perform code reviews following Sentry engineering practices. Use when reviewing pull requests, examining code changes, or providing feedback on code quality. Covers security, performance, testing, and design review.

日本語の概要は準備中です。原文の説明を表示しています。

Launch multiple explore subagents in parallel to investigate architecture, data models, auth, APIs, and deployment. Synthesize into an onboarding document.

日本語の概要は準備中です。原文の説明を表示しています。

Creative research ideation and exploration. Use for open-ended brainstorming sessions, exploring interdisciplinary connections, challenging assumptions, or identifying research gaps. Best for early-stage research planning when you do not have specific observations yet. For formulating testable hypotheses from data use hypothesis-generation.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end observational epidemiology analysis — from research question (PECO Population/Exposure/Comparator/Outcome) to publication-ready statistical report. Covers cohort/case-control/cross-sectional design, regression with confounders, propensity scoring, sensitivity analysis. Writes Python code for every step. Use for epidemiology study analysis, NHANES/UK-Biobank-style analyses.

日本語の概要は準備中です。原文の説明を表示しています。

Architectures and techniques for neural operators on discontinuous PDE solutions (shocks, contact discontinuities, steep gradients). Covers local-global spectral design (ShockFNO), reflection padding for non-periodic BCs, resolution scaling for shock width, and frequency-band error diagnostics. Use for low-viscosity Burgers, compressible Euler, Riemann problems, or any PDE where standard FNO produces Gibbs oscillations.

日本語の概要は準備中です。原文の説明を表示しています。

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 7.

日本語の概要は準備中です。原文の説明を表示しています。

Controls error rates across thousands of simultaneous tests in genomics discovery using false-discovery-rate methods (Benjamini-Hochberg 1995; Benjamini-Yekutieli 2001 for arbitrary dependence; Storey q-value with pi0 estimation; local FDR; independent filtering Bourgon 2010; covariate-weighted FDR via IHW Ignatiadis 2016), plus family-wise error control (Bonferroni, Holm) and the GWAS genome-wide threshold. Covers the FDR-versus-FWER choice as the discovery-versus-confirmatory distinction, the dependence assumptions behind BH (PRDS) versus BY, pi0 estimation, the independent-filtering and false-coverage-rate traps, and reproducibility ranking via IDR (Li 2011). Use when correcting p-values from genome-wide tests, choosing between BH/BY/q-value/Bonferroni, setting an FDR threshold, applying IHW or independent filtering, or interpreting q-values. For confirmatory trials with few pre-specified endpoints (closed testing, graphical/gatekeeping), see clinical-biostatistics/multiplicity-graphical.

日本語の概要は準備中です。原文の説明を表示しています。

Performs subgroup and heterogeneous treatment effect (HTE) analyses for clinical trials. Covers Mantel-Haenszel pooling, Breslow-Day, interaction tests in regression, RERI for additive interaction, modern data-adaptive HTE methods (STEPP, SIDES, causal forests, X/R-learners), Bayesian shrinkage (Dixon-Simon, MAP, EXNEX), graphical multiplicity (Bretz-Maurer), and credibility frameworks (Sun BMJ, EMA 2019). Use when analyzing treatment effects across patient subgroups for regulatory submissions or precision-medicine claims.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Build circular genome visualizations using circlize (R), pyCirclize (Python), or Circos (Perl CLI) with ideogram tracks, multi-data tracks (scatter, histogram, heatmap), chord/link arcs for interactions, and explicit circos.clear() between plots. Covers when circular is appropriate vs when Cartesian wins (Cleveland-McGill 1984), karyograms, and chromosome adjacency in chord diagrams. Use when adjacency on the circle conveys meaning — chromosome-level overview, structural variants, Hi-C interactions, cross-genome comparisons.

日本語の概要は準備中です。原文の説明を表示しています。

Deep literature review — PubMed, EuropePMC, bioRxiv preprints, citation networks, evidence synthesis. Disambiguates queries, runs collision-aware searches, grades evidence T1-T4, and produces structured reports. Use for systematic literature review, meta-analysis evidence collection, and detailed answer-with-citations workflows.

日本語の概要は準備中です。原文の説明を表示しています。

Nonlinear curve fitting for physics data with proper error propagation, chi-squared analysis, residual diagnostics, confidence intervals, and model comparison (AIC/BIC). Use for any parameter extraction from experimental or simulation data.

日本語の概要は準備中です。原文の説明を表示しています。

Evaluate LLM outputs using frontier models as judges. Use for pairwise model comparison, quality scoring with custom rubrics, and automated evaluation pipelines. Covers position bias mitigation, statistical significance, and generating preference data for DPO/RLHF.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end proteomics workflow from MaxQuant output to differential protein abundance. Orchestrates data import, normalization, imputation, and statistical testing with limma (default) or MSstats for complex feature-level designs. Use when processing mass spectrometry proteomics.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end neoantigen discovery from somatic variants to ranked vaccine candidates. Integrates HLA typing, MHC binding prediction, pVACtools neoantigen calling, and immunogenicity scoring. Use when identifying tumor neoantigens for personalized vaccine design or checkpoint biomarkers.

日本語の概要は準備中です。原文の説明を表示しています。

End-to-end shotgun metagenomics workflow from FASTQ to taxonomic and functional profiles, orchestrating controls/host depletion, Kraken2+Bracken classification, MetaPhlAn marker profiling, and HUMAnN functional profiling. Covers the controls-first ordering, why Kraken2 read counts are not abundances and MetaPhlAn cell fractions do not equal Bracken read fractions, and the consistent-pipeline framing. Use when profiling shotgun metagenomic samples end to end, or chaining classification, abundance, and function. For resistome see metagenomics/amr-detection; for strains see metagenomics/strain-tracking; for assembly see genome-assembly/metagenome-assembly.

日本語の概要は準備中です。原文の説明を表示しています。

Orchestrates an end-to-end long-read structural-variant pipeline - basecalling to minimap2 alignment (platform-matched preset) to Sniffles2/cuteSV/pbsv calling to optional assembly-based calling (dipcall/PAV) to two-step .snf cohort merging to Truvari benchmarking - chaining ONT and PacBio HiFi runs while handing the SV signal mechanism off to the component skills. Use when running a long-read SV workflow from reads to a benchmarked callset, choosing the minimap2 preset and SV caller by platform and goal, deciding when long reads are worth it for the insertions and repeat-mediated SVs short reads physically miss, building a joint-genotyped cohort with the two-step .snf design, or parameterizing a Truvari benchmark against GIAB HG002 Tier 1 plus CMRG. Not for the SV signal mechanism itself (see variant-calling/structural-variant-calling) or short-read SV.

日本語の概要は準備中です。原文の説明を表示しています。

Statistical models library for Python. Use when you need specific model classes (OLS, GLM, mixed models, ARIMA) with detailed diagnostics, residuals, and inference. Best for econometrics, time series, rigorous inference with coefficient tables. For guided statistical test selection with APA reporting use statistical-analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Transform GWAS signals into drug targets and repurposing opportunities. Connects GWAS-significant loci to causal genes via fine-mapping/eQTL, then to druggable proteins via DGIdb/OpenTargets, then to existing drugs via ChEMBL. Use for GWAS-to-target hypothesis generation, druggable-fraction analysis of disease loci, and human-genetics-validated drug-repurposing prioritization.

日本語の概要は準備中です。原文の説明を表示しています。

Identify drug repurposing candidates via target-based, compound-based, and disease-based strategies. Combines drug-target-disease network reasoning with mechanism rationale, clinical-trial precedent, and patent/regulatory feasibility. Use for hypothesis-generating repurposing for orphan diseases, finding existing drugs for new indications, and prioritizing candidates by evidence and feasibility.

日本語の概要は準備中です。原文の説明を表示しています。

Multi-objective optimization framework. NSGA-II, NSGA-III, MOEA/D, Pareto fronts, constraint handling, benchmarks (ZDT, DTLZ), for engineering design and optimization problems.

日本語の概要は準備中です。原文の説明を表示しています。